These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7985753)

  • 1. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant.
    Hoffman SL; Edelman R; Bryan JP; Schneider I; Davis J; Sedegah M; Gordon D; Church P; Gross M; Silverman C
    Am J Trop Med Hyg; 1994 Nov; 51(5):603-12. PubMed ID: 7985753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine.
    Rickman LS; Gordon DM; Wistar R; Krzych U; Gross M; Hollingdale MR; Egan JE; Chulay JD; Hoffman SL
    Lancet; 1991 Apr; 337(8748):998-1001. PubMed ID: 1673211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model.
    Amelia F; Iyori M; Emran TB; Yamamoto DS; Genshi K; Otsuka H; Onoue Y; Yusuf Y; Islam A; Yoshida S
    Parasite Immunol; 2019 May; 41(5):e12624. PubMed ID: 30883819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
    Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
    PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.
    Zenklusen I; Jongo S; Abdulla S; Ramadhani K; Lee Sim BK; Cardamone H; Flannery EL; Nguyen T; Fishbaugher M; Steel RWJ; Betz W; Carmago N; Mikolajczak S; Kappe SHI; Hoffman SL; Sack BK; Daubenberger C
    J Infect Dis; 2018 Apr; 217(10):1569-1578. PubMed ID: 29438525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.
    Friedman-Klabanoff DJ; Berry AA; Travassos MA; Shriver M; Cox C; Butts J; Lundeen JS; Strauss KA; Joshi S; Shrestha B; Mo AX; Nomicos EYH; Deye GA; Regules JA; Bergmann-Leitner ES; Pasetti MF; Laurens MB
    J Infect Dis; 2024 Jun; 229(6):1883-1893. PubMed ID: 38330357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.
    Wang LT; Pereira LS; Kiyuka PK; Schön A; Kisalu NK; Vistein R; Dillon M; Bonilla BG; Molina-Cruz A; Barillas-Mury C; Tan J; Idris AH; Francica JR; Seder RA
    PLoS Pathog; 2021 Dec; 17(12):e1010133. PubMed ID: 34871332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.
    Brown AE; Singharaj P; Webster HK; Pipithkul J; Gordon DM; Boslego JW; Krinchai K; Su-archawaratana P; Wongsrichanalai C; Ballou WR
    Vaccine; 1994 Feb; 12(2):102-8. PubMed ID: 8147091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
    Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
    Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.
    Sherwood JA; Copeland RS; Taylor KA; Abok K; Oloo AJ; Were JB; Strickland GT; Gordon DM; Ballou WR; Bales JD; Wirtz RA; Wittes J; Gross M; Que JU; Cryz SJ; Oster CN; Roberts CR; Sadoff JC
    Vaccine; 1996 Jun; 14(8):817-27. PubMed ID: 8817830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.
    Scally SW; Murugan R; Bosch A; Triller G; Costa G; Mordmüller B; Kremsner PG; Sim BKL; Hoffman SL; Levashina EA; Wardemann H; Julien JP
    J Exp Med; 2018 Jan; 215(1):63-75. PubMed ID: 29167197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.
    Cummings JF; Polhemus ME; Kester KE; Ockenhouse CF; Gasser RA; Coyne P; Wortmann G; Nielsen RK; Schaecher K; Holland CA; Krzych U; Tornieporth N; Soisson LA; Angov E; Heppner DG;
    Vaccine; 2024 Apr; 42(12):3066-3074. PubMed ID: 38584058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.